Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung
The purpose of this study is to test whether 5 fraction stereotactic ablative body radiation (SABR) is safe and improves local control for early state squamous cell carcinoma of the lung. While three fraction SABR is effective for the treatment of early stage non small cell lung carcinoma (NSCLC) of all histologies, it is not safe for many patients. While four and five fraction SABR is safe, recently published data and our institutional data suggests that local control for early stage squamous cell carcinoma of the lung using the current four or five fraction SABR is suboptimal.
Checked against the public recordLast updated Jul 26, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Indiana University
- Interventions being studied
- Radiation: Stereotactic Ablative Body Radiation (SABR)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria 1. Age ≥ 18 at time of consent. 2. Ability to provide written informed consent and HIPAA authorization. 3. Pathological diagnosis of squamous cell carcinoma of the lung. 4. Staging PET/CT (invasive mediastinal staging strongly encouraged but not required). 5. Tumors \< 7cm 6. Any location eligible for SBRT (including, but not limited to, peripheral, chest wall abutting and central tumors) 7. N0 M0 disease 8. Plan to undergo four or five fraction SABR 9. Baseline PFTs available within 6 months of treatment start or will be obtained prior to treatment start (no finding will exclude patient from enrollment in trial) Exclusion Criteria 1. Previous radiation therapy to the lung per investigator discretion. 2. Inability to comply with treatment per investigator discretion. 3. Inability to follow standard of care follow up recommendations per investigator discretion. 4. KPS\<40
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Indiana University Health HospitalIndianapolis, Indiana
- Indiana University Health Methodist HospitalIndianapolis, Indiana
- Indiana University Melvin and Bren Simon Cancer CenterIndianapolis, Indiana
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 26, 2022. Always confirm current availability with the study team.